Street canvu MBX phase II HP data more than one way

▤ Summary

MBX Biosciences has reported full phase II data for canvuparatide in hypoparathyroidism. The results position the drug against Ascendis Pharma’s Yorvipath, which is already FDA-cleared. The article frames the data as part of a competitive readout in endocrine disease rather than a corporate transaction or personnel move. The content is primarily about a biopharma clinical development update.

▦ Linked Companies